BBOT
BridgeBio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
BBOT Profile
Bridgebio Oncology Therapeutics, Inc.
A clinical-stage biopharmaceutical company headquartered in South San Francisco,California,USA
Biological Technology
06/15/2021
02/09/2024
NASDAQ Stock Exchange
3
12-31
--
Common stock
256 E. Grand Avenue
Suite 104
South San Francisco
CA 94080
--
BridgeBio Oncology Therapeutics, Inc., was incorporated as a Cayman Islands exempted company on June 15, 2021. Effective August 12, 2025, the Company completed the previously announced Business Combination, with the combined company's place of incorporation in Delaware. BBOT is a clinical-stage biotechnology company whose mission is to transform the lives of cancer patients driven by the two most commonly mutated oncogenes, RAS and PI3Kα.
